drug · small molecule
baricitinib
Marketedupdated 3mo agoby Eli Lilly and Co🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 31 investigational indications.
indications
investigational
Rheumatoid Arthritis
targets
Tyrosine-protein kinase JAK1Tyrosine-protein kinase JAK2
all catalysts(0)
nothing on the calendar yet
Trials studying baricitinib
- phase3A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
- phase3A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
- phase3Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica
- phase3A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
- phase2Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease
- phase3A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
- phase3A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis
- phase2Baricitinib Curative Repression of HIV-1
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 10, 2029
~2.6 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (17)
- Nov 30, 2032method-of-use (U-3372)US 11045474
- Nov 30, 2032method-of-use (U-3372)US 11045474
- Nov 30, 2032method-of-use (U-3372)US 11045474
- Nov 30, 2032method-of-use (U-3372)US 9089574
- Nov 30, 2032method-of-use (U-3372)US 9089574
- Nov 30, 2032method-of-use (U-3372)US 9089574
- May 31, 2032compositionUS 8158616
- May 31, 2032compositionUS 8158616
- May 31, 2032compositionUS 8158616
- Nov 2, 2031method-of-use (U-3500)US 11806555
- Nov 2, 2031method-of-use (U-3500)US 11806555
- Nov 2, 2031method-of-use (U-3500)US 11806555
- Nov 2, 2031method-of-use (U-3500)US 9737469
- Nov 2, 2031method-of-use (U-3500)US 9737469
- Nov 2, 2031method-of-use (U-3500)US 9737469
- Mar 10, 2029method-of-use (U-247)US 84206292.6y
- Mar 10, 2029method-of-use (U-247)US 84206292.6y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 30m ago
Found something off?
comments(0)
5-min edit window · permanent after that